Negative symptoms

Negative Symptoms - The Great Absence

Represents a deficit of normal functions, contributing significantly to morbidity. These symptoms are often less responsive to older antipsychotic medications compared to positive symptoms.

📌 The 5 A's:

• Affective flattening: Blunted emotional expression.
• Alogia: Poverty of speech.
• Avolition: Decreased motivation.
• Anhedonia: Inability to feel pleasure.
• Asociality: Social withdrawal.

⭐ Negative symptoms are strong predictors of poor long-term functional outcome, including deficits in employment and independent living.

The 5 A's - Apathy's Alphabet

📌 Mnemonic: "The 5 A's" detail the absence or reduction of normal functions. These symptoms are core features of schizophrenia and are linked to significant long-term disability.

• Alogia: Poverty of speech; diminished quantity of speech or content.
• Affective Flattening: Restricted range and intensity of emotional expression. Face appears immobile and unresponsive.
• Anhedonia: Decreased ability to experience pleasure from positive stimuli.
• Avolition: Decrease in motivated, self-initiated purposeful activities. Includes apathy and poor hygiene.
• Asociality: Apparent lack of interest in social interactions.

⭐ Exam Favorite: Negative symptoms are major contributors to poor functional outcomes in schizophrenia and are generally less responsive to older, typical antipsychotic medications compared to positive symptoms.

Brain Drain - The Cortical Connection

• Underlying cause: Hypoactivity in the mesocortical dopamine pathway, leading to ↓ dopamine in the prefrontal cortex (PFC).
• This cortical dopamine deficit impairs executive functions, manifesting as the "5 A's":
  • Affective flattening: Blunted emotional expression.
  • Alogia: Poverty of speech.
  • Avolition/Apathy: ↓ goal-directed behavior.
  • Anhedonia: Inability to feel pleasure.
  • Asociality: Social withdrawal.

⭐ Dopamine Imbalance: This mesocortical hypoactivity often co-exists with mesolimbic pathway hyperactivity (causing positive symptoms), a key concept for treatment.

Rule-Outs - Not Just the Blues

• Depression (MDD): Differentiated by pervasive low mood, anhedonia in all contexts, and significant guilt/worthlessness.
• Medication Side Effects: Antipsychotic-induced Extrapyramidal Symptoms (EPS), especially bradykinesia and akinesia, can mimic avolition and flat affect.
• Substance Use: Chronic cannabis or sedative use may induce a separate amotivational syndrome.
• Social Deprivation: Severe understimulation can cause apathy mimicking negative symptoms.

⭐ Differentiating primary vs. secondary negative symptoms is a key clinical step. Secondary symptoms may be reversible by treating depression, reducing antipsychotic dose to alleviate EPS, or managing substance use.

Treatment - The Uphill Battle

• Limited Efficacy: Negative symptoms are notoriously difficult to treat compared to positive symptoms, often persisting despite medication.
• Pharmacotherapy:
  • Second-generation (atypical) antipsychotics are first-line (e.g., risperidone, olanzapine); they have modest benefits over first-generation agents.
  • Newer agents like cariprazine and amisulpride may show greater efficacy.
• Psychosocial Interventions (Crucial Adjuncts):
  • Cognitive Behavioral Therapy (CBTp)
  • Social skills training
  • Supported employment

⭐ Cariprazine's potential efficacy for negative symptoms is linked to its high affinity and partial agonist activity at dopamine D3 receptors, distinguishing it from other atypicals.

High-Yield Points - ⚡ Biggest Takeaways

• Negative symptoms, the 5 A's (Avolition, Alogia, Anhedonia, Asociality, Affective flattening), are major drivers of poor functional outcome.
• They are associated with dopamine hypofunction in the mesocortical pathway.
• Unlike positive symptoms, they show a poor response to first-generation (typical) antipsychotics.
• Second-generation (atypical) antipsychotics may offer slightly better, though often limited, efficacy.
• Their presence is a strong predictor of a worse long-term prognosis.